ACAT1 loss impairs TNFα-induced SOX4 accumulation and triggers lipid- dependent growth suppression in ERG-negative prostate cancer
This study demonstrates that in ERG-negative prostate cancer, the loss of ACAT1 impairs TNFα-induced SOX4 protein accumulation and triggers lipid-dependent growth suppression through metabolic remodeling and PPARγ activation, highlighting a critical link between ACAT1-mediated lipid homeostasis and tumor progression.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Prostate cancer is not a single disease but a collection of different conditions that behave in unique ways. Some tumors grow slowly and respond well to hormone therapy, while others become aggressive, spread to other parts of the body, and resist standard treatments. A key factor that helps doctors distinguish between these different types is a specific genetic feature called ERG. In many prostate cancers, a piece of DNA breaks and reattaches in a way that turns on a gene named ERG. This genetic change creates two broad groups of patients: those whose tumors carry the ERG switch and those whose do not. While scientists have long known that these two groups differ in their genetics and behavior, it has remained unclear whether their internal chemistry—the way they process energy and nutrients—also changes differently as the disease worsens. Understanding these metabolic differences is crucial because cancer cells must constantly rewire their internal fuel systems to survive and spread, and these rewiring patterns could reveal new ways to stop them.
A team of researchers recently set out to map these metabolic differences, focusing specifically on the group of patients whose tumors lack the ERG gene. By analyzing genetic data from hundreds of patients and combining it with detailed studies of cancer cells in the lab, they discovered a distinct pattern in the aggressive, treatment-resistant versions of ERG-negative cancer. These cells showed a surprising drop in their ability to process certain fats and amino acids, yet they relied heavily on a specific enzyme called ACAT1 to keep growing. ACAT1 acts like a molecular tool inside the cell's power plants, helping to manage energy and fat storage. The researchers found that when this enzyme is present, the cancer cells thrive, but when it is removed, the cells struggle to survive.
The study revealed that ACAT1 does more than just manage energy; it also acts as a guardian for a critical protein called SOX4. In healthy cells, SOX4 helps regulate how cells grow and change, but in these aggressive cancer cells, the amount of SOX4 protein depends entirely on the presence of ACAT1. When the researchers removed ACAT1, the levels of SOX4 protein plummeted, even though the instructions to make the protein remained unchanged. This suggested that ACAT1 protects SOX4 from being broken down by the cell's natural recycling system. Without ACAT1, the cancer cells could not maintain the high levels of SOX4 needed to drive their rapid growth, and they began to slow down and eventually stop dividing.
This breakdown of SOX4 triggered a chain reaction that disrupted the cell's entire internal economy. The removal of ACAT1 caused a buildup of fats and lipids that the cell could not properly use. Normally, cells can burn these fats for energy, but in this case, the fats simply piled up, creating a toxic environment that halted cell division. The researchers tested whether this fat buildup was the direct cause of the growth stop by changing the food the cells ate. When they fed the cells a diet stripped of external fats, the harmful buildup disappeared, and the cells began to grow again. This proved that the cancer cells had become dependent on a specific balance of fats, and without ACAT1 to manage that balance, the presence of fats actually hurt them.
Further investigation showed that the cell's response to this fat imbalance involved a master regulator called PPARγ. When ACAT1 was missing, the levels of PPARγ rose, which in turn encouraged the cell to store even more fat and stop growing. The researchers confirmed this link by using a drug to block PPARγ; when they did this, the fat buildup decreased, and the cells regained some of their ability to multiply. This suggests that the cell's attempt to cope with the loss of ACAT1 by activating PPARγ actually backfired, turning a survival mechanism into a growth-suppressing trap.
The study also looked at how these findings played out in real human tissue. By examining samples from patients, the researchers found that ACAT1 and SOX4 often appeared in the same spots within the tumor, specifically in areas outside the cell's nucleus. This spatial connection supported the idea that the two molecules work together in the living tissue, not just in lab dishes. Interestingly, this dependency on ACAT1 was specific to the ERG-negative group. When the researchers tested cells that did have the ERG gene, removing ACAT1 had little effect on their growth or fat levels. This highlights that the internal chemistry of prostate cancer is not uniform; what drives one type of tumor may be irrelevant to another.
Ultimately, the research paints a clear picture of how a specific genetic background shapes the metabolic vulnerabilities of a cancer. In ERG-negative prostate cancer, the enzyme ACAT1 is essential for maintaining a delicate balance of proteins and fats. Without it, the cell's internal systems collapse under the weight of its own lipids, and its growth machinery shuts down. While the study was conducted primarily in laboratory settings, it aligns with previous observations that high levels of ACAT1 are found in aggressive, treatment-resistant tumors. The findings suggest that targeting the metabolic pathways controlled by ACAT1, or the fat-handling systems that go awry when it is lost, could offer a new strategy for treating this specific subset of prostate cancer patients. The work does not claim to have found a cure, but it has identified a precise point of weakness in the cancer's armor, one that depends on the unique genetic makeup of the tumor.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.